Lilly lung cancer med up for FDA panel review; AZ, Ironwood eye China filing for Linzess;

> Eli Lilly's ($LLY) experimental lung cancer drug nectumumab is set for an FDA advisory panel meeting Thursday, with agency reviewers asking the expert members to address the drug's blood-clotting risks. Report

> AstraZeneca ($AZN) and partner Ironwood ($IRWD) said their constipation drug Linzess met its goals in a new trial aimed at a regulatory filing in China. Report

> Sanofi ($SNY) is taking two new malaria combo treatments into Phase IIb trials, with one of the artemisinin-free meds--OZ439/Piperquine--already in study and the other--OZ439/Ferroquine--set to start this summer. Release | Report

> Eisai rolled out its epilepsy drug Fycompa for a new indication in the U.K., for another type of seizures. Report

> Hi-Tech Pharmaceuticals snapped up another company in the nutrition and weight loss field, Innovative Laboratories, to expand in diet remedies in the U.S. Release

> Novo Nordisk ($NVO) picked up a set of awards for its investor relations work, including a best-in-class nod for large-cap companies in Europe. Report

And Finally... Oregon has dramatically expanded women's access to birth control. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?